The clinical trials evaluating the anti-coronavirus medication MIR 19 for outpatient use have reached completion. This update was confirmed by Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA). The report indicates that a comprehensive assessment is underway to broaden the approved indications for the drug. Industry observers anticipate that MIR 19 could enter the Russian market by late August this year, subject to regulatory review and safety confirmations.
In the latest findings, MIR 19 demonstrated activity against all coronavirus strains tested in the program, including variants such as delta and omicron, with additional strains evaluated in ongoing studies. The medication is delivered via inhalation using medical nebulizers, a route designed to optimize airway deposition and early antiviral effect. To date, MIR 19 has been deployed primarily within hospital settings, where close monitoring supports dose adjustments and evaluation of patient response.
This week’s communications reaffirm that the drug is intended for use in hospital contexts initially, with plans to extend treatment to outpatient environments once approvals are secured and protocols are aligned with primary care workflows. The FMBA’s briefings emphasize that MIR 19 would be most effective when administered in the initial days following a positive COVID-19 test, aiming to reduce progression and facilitate recovery for at-risk populations.
In related developments, early reports had indicated regulatory activity in Russia surrounding a new COVID-19 medication named MIR 19, with conversations centering on hospital-based use. The FMBA’s public summaries make clear that the intended pathway involves early administration during confirmed infection, integrating MIR 19 into clinical management strategies in the days immediately after diagnosis. The broader intent is to establish a practical framework for outpatient adoption while maintaining rigorous safety monitoring and post-marketing surveillance. These steps align with established health authority practices observed in prior phases of antiviral rollout and continue to be a focal point for healthcare providers and patient advocates worldwide.
Earlier communications also noted that Russia had registered a novel antiviral candidate for COVID-19, Esperavir, signaling a broader effort to expand the national therapeutic arsenal. While Esperavir represents a separate development track, MIR 19’s progression through trials and regulatory review holds particular significance for its potential to complement existing treatment options. In the interim, clinicians are urged to follow official guidance, integrate MIR 19 into appropriate clinical pathways, and participate in pharmacovigilance programs to ensure ongoing safety and effectiveness across patient populations. Attribution: FMBA communications and internal reviews.